How can the industry transform itself with improved biomarkers for clinical development? And what hurdles stand in the way? We sat down with senior representatives from Galapagos, Ohio State University, and Genentech to find out more.

Melanie Anderson, Principal Scientist at MSD, on how the pandemic has made scientists rethink clinical trials.